Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2013


Nanomedicine 2013

11 Apr 2013 - 12 Apr 2013 - Barcelona, Spain



Bookmark and Share


Market researchers have estimated that the Nanomedicine industry was worth over $72.8billion in 2011 and is expected to grow rapidly to the level of influencing entire economies. Due to major advances in science and engineering, the relatively young field of nanotechnology has been expanding significantly. Despite the exciting advancements in this discipline, which involves miniscule manufactured products 1 – 100nm in size, the field of nanomedicine has yet to be exploited to its full potential. A large part of the nanomedicine industry is within the use of nanoparticles for the treatment of cancerous tumors. However, many nanoparticles show signs of toxicity in cells and this can be caused by the inherent properties, size and surface charge of the particles. This leaves the door open for engineered solutions to enable nanomedicine to continue progressing at its historic rate.

This conference will aim to provide a multidisciplinary approach to tackle the fundamental challenges in this speciality, innovative strategies for testing exposure, and techniques for improving the reliability and accuracy of results.

The conference will be co-located with our ADME & PT meeting. Registered delegates will have unrestricited access to both meetings ensuring a comprehensive learning and sharing experience as well as being financially beneficial for attendees.



Further information
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!